Germany: Ampersand adds to investment in ProtaGene

ProtaGene, a Germany-based global contract research organization (CRO) dedicated to advanced analytics for biologics and cell and gene therapies, has received additional investment from Ampersand Capital Partners. Ampersand has invested nearly US$40m within the past year to support ProtaGene’s services and capacity expansions. Investment has supported ProtaGene’s worldwide expansion efforts, including establishing cutting-edge facilities in North America and Europe. It…

You must be a HMI Subscriber to view this content.

Subscribe Now »